Skip to content

A study to assess Whether Kalium arsenicosum helps to relieve severe itching in fungal infection of skin.

A PROSPECTIVE STUDY TO ASSESS THE LIKELIHOOD RATIO FOR THE SYMPTOM INTOLERABLE ITCHING, WORSE UNDRESSING OF KALIUM ARSENICOSUM IN CASES OF TINEA CORPORIS AND TINEA CRURIS - NOT APPLICABLE

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065346
Enrollment
88
Registered
2024-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis Health Condition 2: B356- Tinea cruris

Interventions

Intervention1: Indicated Homoeopathic Medicine or Kalium arsenicosum: All the eligible patients having the symptoms of tinea corporis and tinea cruris will be prescribed homeopathic medicines. Prescri

Sponsors

Dr MPK Homoeopathic Medical College Hospital And Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of both sexes presenting with Tinea corporis ICD-10 code B35.4 or Tinea cruris ICD 10 code B35.6 based on clinical history and physical examination findings Previously diagnosed cases of tinea corporis or tinea cruris recurring after other medicinal treatments providing no avail after a washout period of 14 days As per sign and symptoms adopted from Illustrated Synopsis of Dermatology and Sexually Transmitted Diseases 4th edition. Patients with following signs and symptoms given below shall be enrolled for the study 1.Severe itching 2.Annular or Arcuate lesion 3.Periphery shows papulovesiculation and scaling and relative clearing at centre 4.Site of infection Trunk, limbs, flexures and groin Diagnostic criteria 1.Symptoms mentioned above 2.Potassium hydroxide scraping test done if required in case of unclear symptoms given above

Exclusion criteria

Exclusion criteria: Patients who refuse to give consent for the study Cases with other severe systemic or psychiatric illness will be excluded from the study Patients having tinea corporis or tinea cruris which is secondary to DM and Hypertension etc. will be excluded Patients unwilling to participate or to comply with the study requirements

Design outcomes

Primary

MeasureTime frame
According to the scores obtained (pre and post treatment) from the Dermatological Life Quality Index (DLQI)Timepoint: Pre scores will be taken at baseline of treatment and post score will be assessed at the end of 12 weeks using Dermatological Life Quality Index (DLQI)

Secondary

MeasureTime frame
To assess the likelihood ratio of the symptom intolerable itching worse undressing of Kalium arsenicosum in patients of tinea corporis and tinea cruris To assess the effectiveness of kali arsenicosum in cases of tinea corporis and tinea cruris Timepoint: 12 months

Countries

India

Contacts

Public ContactDr Navroop Bhatia

Dr MPK Homoeopathic Medical College Hospital And Research Centre

soniatuteja860@gmail.com9530454132

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026